gemfibrozil has been researched along with Stroke in 10 studies
Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
| Excerpt | Relevance | Reference |
|---|---|---|
| "In men with coronary heart disease, low HDL cholesterol, and low LDL cholesterol, gemfibrozil reduces stroke incidence." | 9.09 | Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT). ( Babikian, V; Bloomfield Rubins, H; Brass, LM; Collins, D; Davenport, J; Papademetriou, V; Robins, SJ; Rutan, G; Wagner, S; Wexler, L, 2001) |
| "In men with coronary heart disease, low HDL cholesterol, and low LDL cholesterol, gemfibrozil reduces stroke incidence." | 5.09 | Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT). ( Babikian, V; Bloomfield Rubins, H; Brass, LM; Collins, D; Davenport, J; Papademetriou, V; Robins, SJ; Rutan, G; Wagner, S; Wexler, L, 2001) |
| " Efficacy of gemfibrozil was demonstrated in secondary stroke prevention in patients with coronary heart disease and elevated triglyceride levels." | 4.89 | Hypertriglyceridemia as a possible independent risk factor for stroke. ( Basić-Kes, V; Demarin, V; Lisak, M; Trkanjec, Z, 2013) |
| "Since dyslipidemia is common in diabetes and is associated with increased cardiovascular risk, we tested the hypothesis that Thr-54 is associated with increased cardiovascular risk in patients with diabetes." | 2.73 | Codon 54 polymorphism of the fatty acid binding protein (FABP) 2 gene is associated with increased cardiovascular risk in the dyslipidemic diabetic participants of the Veterans Affairs HDL intervention trial (VA-HIT). ( Bloomfield, H; Brousseau, ME; Collins, D; Georgopoulos, A; O'Connor, JJ; Ordovas, JM; Robins, SJ; Schaefer, EJ, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (70.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lisak, M | 1 |
| Demarin, V | 1 |
| Trkanjec, Z | 1 |
| Basić-Kes, V | 1 |
| Wang, D | 1 |
| Liu, B | 1 |
| Tao, W | 1 |
| Hao, Z | 1 |
| Liu, M | 1 |
| Jakob, T | 1 |
| Nordmann, AJ | 1 |
| Schandelmaier, S | 1 |
| Ferreira-González, I | 1 |
| Briel, M | 1 |
| Corvol, JC | 1 |
| Bouzamondo, A | 1 |
| Sirol, M | 1 |
| Hulot, JS | 1 |
| Sanchez, P | 1 |
| Lechat, P | 1 |
| Georgopoulos, A | 1 |
| Bloomfield, H | 1 |
| Collins, D | 3 |
| Brousseau, ME | 1 |
| Ordovas, JM | 1 |
| O'Connor, JJ | 1 |
| Robins, SJ | 3 |
| Schaefer, EJ | 1 |
| Nelson, JJ | 1 |
| Bloomfield, HE | 1 |
| Asztalos, BF | 1 |
| Plutzky, J | 1 |
| Ridker, PM | 1 |
| Athyros, VG | 1 |
| Papageorgiou, AA | 1 |
| Kontopoulos, AG | 1 |
| Bloomfield Rubins, H | 1 |
| Davenport, J | 1 |
| Babikian, V | 1 |
| Brass, LM | 1 |
| Wexler, L | 1 |
| Wagner, S | 1 |
| Papademetriou, V | 1 |
| Rutan, G | 1 |
| Rizos, E | 1 |
| Mikhailidis, DP | 1 |
5 reviews available for gemfibrozil and Stroke
| Article | Year |
|---|---|
Hypertriglyceridemia as a possible independent risk factor for stroke.
Topics: Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Gemfibrozil; Humans; Hypertriglyceridemia; Hyp | 2013 |
Fibrates for secondary prevention of cardiovascular disease and stroke.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Bezafibrate; Cardiovascular Diseases; Caus | 2015 |
Fibrates for primary prevention of cardiovascular disease events.
Topics: Atorvastatin; Bezafibrate; Cardiovascular Diseases; Clofibric Acid; Fenofibrate; Gemfibrozil; Humans | 2016 |
Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials.
Topics: Anticholesteremic Agents; Atorvastatin; Cholestyramine Resin; Clofibrate; Colestipol; Gemfibrozil; H | 2003 |
Are high density lipoprotein (HDL) and triglyceride levels relevant in stroke prevention?
Topics: Adult; Bezafibrate; Biomarkers; Cholesterol; Coronary Disease; Female; Follow-Up Studies; Gemfibrozi | 2001 |
3 trials available for gemfibrozil and Stroke
| Article | Year |
|---|---|
Codon 54 polymorphism of the fatty acid binding protein (FABP) 2 gene is associated with increased cardiovascular risk in the dyslipidemic diabetic participants of the Veterans Affairs HDL intervention trial (VA-HIT).
Topics: Aged; Codon; Diabetes Mellitus; Dyslipidemias; Fatty Acid-Binding Proteins; Gemfibrozil; Genetic Pre | 2007 |
Statin-fibrate combinations in patients with combined hyperlipedemia.
Topics: Clofibric Acid; Coronary Disease; Drug Therapy, Combination; Fibric Acids; Follow-Up Studies; Gemfib | 2001 |
Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT).
Topics: Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Follow-Up Studies; Gemfibrozil; Humans; | 2001 |
2 other studies available for gemfibrozil and Stroke
| Article | Year |
|---|---|
Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Aged; Apolipoproteins B; Cardiovascular Diseases; Ch | 2008 |
Statins for stroke: the second story?
Topics: Anticholesteremic Agents; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Gemfibrozil; | 2001 |